Staff Members - Benha University
Egyptian Association of Vascular Biology and Atherosclerosis Consensus on The Usage of SGLT2 Inhibitors in Heart Failure
European Heart Journal Supplements • 2021
Publication Information
Authors
Ashraf Reda, Ahmed Shawky Elserafy, Elsayed Farag, Tamer Mostafa, Nabil Farag, Atef Elbahary, Osama Sanad, Mohamed Abdelshafy Tabl, Ahmed Bendary, Ahmed Elkersh, Mohamed Ashraf, Ihab Attia, Morad Beshay, Hany Ragy, Mohammed Selim, Hazem Khamis
Keywords
EAVA, Consensus, SGLT2i
Journal
European Heart Journal Supplements
Publisher
Oxford Academics
Volume
23
Issue
D
Pages
Not Available
publication.type
International
Paper Link
Open Link
Supplementary Materials
Not Available
Abstract
Aims
Analysis of SGLT2i data from DAPA-HF and EMPEROR- reduced trials to put a simplified consensus statement on the use of these glucose lowering agents in patients with established heart failure.
Methods and Results
Sixty experts in the field of cardiology revised the literature of the SGLT2i in heart failure, their recommended indications, and their contraindications. Data from DAPA-HF and EMPEROR-reduced trials were tabulated and statistically analysed. SGLT2 inhibitors investigated initially for their glucose lowering capability, have shown a significant benefit in chronic heart failure eit reduced ejection fraction (HFrEF).
Conclusions
We recommend early use of dapagliflozin 10 mg, or empagliflozin 10 mg in patients suffering from symptomatic chronic HFrEF, whether the patient is diabetic or non, to improve heart failure hospitalization, death, symptoms, and decline of renal function.
Analysis of SGLT2i data from DAPA-HF and EMPEROR- reduced trials to put a simplified consensus statement on the use of these glucose lowering agents in patients with established heart failure.
Methods and Results
Sixty experts in the field of cardiology revised the literature of the SGLT2i in heart failure, their recommended indications, and their contraindications. Data from DAPA-HF and EMPEROR-reduced trials were tabulated and statistically analysed. SGLT2 inhibitors investigated initially for their glucose lowering capability, have shown a significant benefit in chronic heart failure eit reduced ejection fraction (HFrEF).
Conclusions
We recommend early use of dapagliflozin 10 mg, or empagliflozin 10 mg in patients suffering from symptomatic chronic HFrEF, whether the patient is diabetic or non, to improve heart failure hospitalization, death, symptoms, and decline of renal function.